Case series of docetaxel, trastuzumab, and pertuzumab (DTP) as first line anti-HER2 therapy and ado-trastuzumab emtansine (T-DM1) as second line for recurrent or metastatic HER2-positive salivary duct carcinoma-Reference-Cited by-同舟云学术

Case series of docetaxel, trastuzumab, and pertuzumab (DTP) as first line anti-HER2 therapy and ado-trastuzumab emtansine (T-DM1) as second line for recurrent or metastatic HER2-positive salivary duct carcinoma

Published:2022-02 Issue: Volume:125 Page:105703
ISSN:1368-8375
Container-title:Oral Oncology
language:en
Short-container-title:Oral Oncology

Author:

Uijen M.J.M.^ORCID,Lassche G.,van Engen-van Grunsven A.C.H.,Driessen C.M.L.,van Herpen C.M.L.

Publisher

Elsevier BV

Subject

Cancer Research,Oncology,Oral Surgery

Reference46 articles.

1. Hubner G;Kleinsasser;Arch Klin Exp Ohren Nasen Kehlkopfheilkd,1968

2. Comprehensive Molecular Characterization of Salivary Duct Carcinoma Reveals Actionable Targets and Similarity to Apocrine Breast Cancer;Dalin;Clinical cancer research : an official journal of the American Association for Cancer Research.,2016

3. Adjuvant androgen deprivation therapy for poor-risk, androgen receptor-positive salivary duct carcinoma. European journal of cancer (Oxford;van Boxtel;England,2019

4. A clinicopathological study and prognostic factor analysis of 177 salivary duct carcinoma patients from The Netherlands;Boon;Int J Cancer,2018

5. Prognostic factors and oncologic outcomes of 56 salivary duct carcinoma patients in a single institution: high rate of systemic failure warrants targeted therapy;Roh;Oral Oncol,2014

Cited by 18 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Prognostic and Predictive Roles of HER2 Status in Non-Breast and Non-Gastroesophageal Carcinomas;Cancers;2024-09-13

2. Salivary gland carcinoma: Towards a more personalised approach;Cancer Treatment Reviews;2024-03

3. Translational Insights in the Landscape of Salivary Gland Cancers: Ready for a New Era?;Cancers;2024-02-28

4. HER2-targeted therapies for salivary gland cancers;Oral Oncology;2024-01

5. Efficacy of Cetuximab Combined with Paclitaxel in Patients with Recurrent Salivary Gland Carcinoma: A Retrospective Observational Study;ORL;2023-12-13